Vivian M Rumjanek
Overview
Explore the profile of Vivian M Rumjanek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliveira T, Lemos D, Jean L, Kawashima J, de Azevedo V, Salustiano E, et al.
Front Oncol
. 2022 Jun;
12:852985.
PMID: 35719932
Chronic Myeloid Leukemia is a neoplastic disease characterized by the abnormal expansion of hematopoietic cells with compromised functions. Leukemic cells often display a multidrug resistance phenotype, enabling them to evade...
2.
de Souza L, Salustiano E, da Costa K, Costa A, Rumjanek V, Domingos J, et al.
Bioorg Chem
. 2021 Mar;
110:104790.
PMID: 33743223
α-aryl-α-tetralones and α-fluoro-α-aryl-α-tetralones derivatives were synthesized by palladium catalyzed α-arylation reaction of α-tetralones and α-fluoro-α-tetralones, with bromoarenes in moderate to good yields. These compounds were evaluated for their in vitro...
3.
Quarti J, Torres D, Ferreira E, Vidal R, Casanova F, Chiarini L, et al.
Molecules
. 2021 Feb;
26(4).
PMID: 33578817
Multidrug resistance (MDR) is the main challenge in the treatment of chronic myeloid leukemia (CML), and P-glycoprotein (P-gp) overexpression is an important mechanism involved in this resistance process. However, some...
4.
Vidal R, Quarti J, Rodrigues M, Rumjanek F, Rumjanek V
Front Oncol
. 2018 Nov;
8:441.
PMID: 30460192
[This corrects the article DOI: 10.3389/fonc.2018.00090.].
5.
da Costa K, Valente R, Silva J, Paiva L, Rumjanek V
An Acad Bras Cienc
. 2018 Oct;
90(3):3081-3097.
PMID: 30304236
Glucocorticoids are produced and released by the adrenal gland and become elevated in response to stress. Although glucocorticoids are well known for their immunosuppressive effects, less is known about their...
6.
Rumjanek V, Maia R, Salustiano E, Costa P
Anticancer Agents Med Chem
. 2018 Apr;
19(1):29-37.
PMID: 29692266
In an attempt to find anticancer agents that could overcome multidrug resistance (MDR), two new classes of modified isoflavonoids were designed and synthesized, and their effectiveness evaluated against a vast...
7.
Vidal R, Quarti J, Rodrigues M, Rumjanek F, Rumjanek V
Front Oncol
. 2018 Apr;
8:90.
PMID: 29675398
Cancer outcome has improved since introduction of target therapy. However, treatment success is still impaired by the same drug resistance mechanism of classical chemotherapy, known as multidrug resistance (MDR) phenotype....
8.
Maia R, Vasconcelos F, Souza P, Rumjanek V
Molecules
. 2018 Jan;
23(1).
PMID: 29316665
: The introduction of imatinib (IM), a tyrosine kinase inhibitor (TKI), has represented a significant advance in the first-line treatment of chronic myeloid leukemia (CML). However, approximately 30% of patients...
9.
Salustiano E, Dumas M, Silva-Santos G, Netto C, Costa P, Rumjanek V
Invest New Drugs
. 2016 May;
34(5):541-51.
PMID: 27189479
Cancer is a malignancy of worldwide prevalence, and although new therapeutic strategies are under investigation, patients still resort to reductive or palliative chemotherapy. Side effects are a great concern, since...
10.
Valente R, Araujo E, Rumjanek V
J Exp Pharmacol
. 2016 May;
4:125-40.
PMID: 27186125
Classically described as a potent inhibitor of the sodium-potassium adenosine triphosphatase enzyme, ouabain has been further shown to act as an effective immunomodulator in mammals. Recently, our group showed that...